Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A phase II pilot study of KW-2189 in patients with advanced renal cell carcinoma
Autore:
Small, EJ; Figlin, R; Petrylak, D; Vaughn, DJ; Sartor, O; Horak, I; Pincus, R; Kremer, A; Bowden, C;
Indirizzi:
Univ Calif San Francisco, UCSF Comprehens Canc Ctr, San Francisco, CA 94115 USA Univ Calif San Francisco San Francisco CA USA 94115 ancisco, CA 94115 USA Univ Calif Los Angeles, UCLA Comprehens Canc Ctr, Los Angeles, CA USA UnivCalif Los Angeles Los Angeles CA USA Canc Ctr, Los Angeles, CA USA Hosp Univ Penn, Philadelphia, PA 19104 USA Hosp Univ Penn Philadelphia PAUSA 19104 Penn, Philadelphia, PA 19104 USA Columbia Presbyterian Med Ctr, New York, NY 10032 USA Columbia Presbyterian Med Ctr New York NY USA 10032 ew York, NY 10032 USA Louisiana State Univ, Med Ctr, Shreveport, LA USA Louisiana State Univ Shreveport LA USA Univ, Med Ctr, Shreveport, LA USA Jansses Res Fdn, Titusville, NJ USA Jansses Res Fdn Titusville NJ USAJansses Res Fdn, Titusville, NJ USA
Titolo Testata:
INVESTIGATIONAL NEW DRUGS
fascicolo: 2, volume: 18, anno: 2000,
pagine: 193 - 197
SICI:
0167-6997(200005)18:2<193:APIPSO>2.0.ZU;2-5
Fonte:
ISI
Lingua:
ENG
Soggetto:
DNA STRAND BREAKS; INTERLEUKIN-2 IL-2; CARBOXYL ESTERASE; INTERFERON-ALPHA; DUOCARMYCINS; INFUSION; ANALOGS; AGENTS;
Keywords:
kidney cancer; KW-2189; duocarmycins;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
24
Recensione:
Indirizzi per estratti:
Indirizzo: Small, EJ Univ Calif San Francisco, UCSF Comprehens Canc Ctr, 2356 Sutter St,5th Floor, San Francisco, CA 94115 USA Univ Calif San Francisco 2356 Sutter St,5th Floor San Francisco CA USA 94115
Citazione:
E.J. Small et al., "A phase II pilot study of KW-2189 in patients with advanced renal cell carcinoma", INV NEW DR, 18(2), 2000, pp. 193-197

Abstract

Background: KW-2189 is a semi-synthetic, water-soluble analog of duocarmycin B-2, a new class of potent antitumor antibiotics produced by streptomyces, with improved in vitro antitumor potency. Patients and methods: Forty patients with pathologically confirmed metastatic renal cell carcinoma were treated in this multicenter, open-label phase II trial. All patients received 0.4 mg/m(2) KW-2189 as an IV infusion for Cycle 1. Cycles were repeated every 5 to 6 weeks with escalations to 0.5 mg/m(2) in the absence of significant toxicity or disease progression. Results: No patient had an objective response. The most common drug-related toxicity was hematological-delayed neutropenia and thrombocytopenia, with recovery by week 6. Non-hematologic toxicity consisted of mild to moderate fatigue, nausea and vomiting, and anorexia that was generally manageable. Conclusions: KW-2189 in this dose and schedule has a predictable safety profile of reversible myelosuppression. No activity in metastatic renal cell carcinoma was demonstrated.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/11/20 alle ore 15:51:15